Rachel Abelman is an Oncology physician affiliated with Harvard University. OpenAlex indexes 70 publications with 579 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Boston, MA 021142621
Telephone
617-231-9943Provider last certified this registry record 29 Jan 2026.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20241 payment
- Novartis Pharmaceuticals CorporationProgram year20241 payment
- Gilead Sciences, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor76%Letrozole100%Part D≥20 patientsOther protein kinase inhibitors24%Truqap100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer
Clinical Cancer Research
2025 - Dynamic Monitoring of Antibody Drug Conjugates Targeting TROP2 or HER2 in Breast Cancer using Circulating Tumor Cells
bioRxiv (Cold Spring Harbor Laboratory)
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Felipe Fregni, MD, MPH
Harvard University
Joseph Antin, MD
Harvard University
Sarah Fortune, MD
Harvard University
Elizabeth Buchbinder, MD
Harvard University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”